Daryl DeKarske is our Senior Vice President, Global Head of Regulatory Affairs and Head of Translational Sciences and has been with Acadia since February 2017.
Mr. DeKarske brings almost 25 years of experience in the biopharmaceutical industry, spanning drug, biologic and device development and life cycle management in multiple therapeutic areas, including in the rare and orphan disease space.
Mr. DeKarske came to Acadia from Shire plc, where he served as Vice President and Global Regulatory Therapeutic Area Head of Neurology, Ophthalmology and Oncology Products and regulatory leadership in support of external business development across all Shire’s therapeutic areas. Previous to that, Mr. DeKarske had global regulatory leadership roles at Sanofi and Searle/Pharmacia in cardiovascular, analgesia/inflammation, hematology and gastrointestinal disorders.
Mr. DeKarske’s career in the biopharmaceutical industry involved clinical and nonclinical research for SmithKline Beecham Corporation and Park-Davis and Company, respectively. Mr. DeKarske earned his Bachelor of Science in Microbiology and Master in Public Health in Toxicology from the University of Michigan.